Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Bridging in CAR-T Treated NHL
NCT05370547Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-Free Survival at 6 months. Started May 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05370547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370547.